Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this post-marketing surveillance is to obtain further information about the tolerability of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| chronic obstructive respiratory tract disease patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Berodual® | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall severity of the clinical picture rated on a 4-point scale | after 3 and 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in dyspnea and/or asthma attacks rated on a 4-point scale | after 3 and 6 weeks | |
| Number of dyspnea episodes rated on a 4-point scale | after 3 and 6 weeks | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Contraindications listed in the Instructions of Use/Summary of Product Characteristics of Berodual® metered-dose inhaler
Not provided
Not provided
Not provided
general practitioners, pneumologists and internists
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| C030809 | fenoterol, ipratropium drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of awakenings due to night-time dyspnea rated on a 4-point scale |
| after 3 and 6 weeks |
| Assessment of morning coughing with expectoration on a 4-point scale | after 3 and 6 weeks |
| Assessment of tolerability on a 4-point scale | after 3 and 6 weeks |
| Number of patients with adverse drug reactions | up to 6 weeks |
| Changes in pathological auscultation findings rated on a 3-point scale | after 3 and 6 weeks |
| Changes in concomitant medication | up to 6 weeks |
| Assessment of efficacy on a 4-point scale | after 3 and 6 weeks |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |